Dapagliflozin and Anemia in Patients with Chronic Kidney Disease

Research output: Contribution to journal › Journal article › Research › peer-review

  • Akihiko Koshino
  • Meir Schechter
  • Glenn M Chertow
  • Priya Vart
  • Niels Jongs
  • Robert D Toto
  • Rossing, Peter
  • Ricardo Correa-Rotter
  • John J V McMurray
  • Jose Luis Górriz
  • Rey Isidto
  • Naoki Kashihara
  • Anna Maria Langkilde
  • David C Wheeler
  • Hiddo J L Heerspink

DAPA and Anemia in Patients with CKDThis post hoc analysis of the DAPA-CKD (Dapagliflozin in Patients with Chronic Kidney Disease) trial assessed the impact of dapagliflozin treatment on the correction and prevention of anemia. Results over a 2.4-year median follow-up show that dapagliflozin is associated with increase in hematocrit, correction of anemia, and reduced risk of incident anemia in patients with CKD with or without type 2 diabetes.

Original languageEnglish
JournalNEJM Evidence
Volume2
Issue number6
ISSN2766-5526
DOIs
Publication statusPublished - 2023

    Research areas

  • Humans, Anemia, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Renal Insufficiency, Chronic

ID: 385016525